Other · developed by TRex Bio
TRB-061 is an investigational agent given as a subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06934252 | Phase 1 | Moderate-to-severe Atopic Dermatitis | Recruiting | TRXB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Moderate-to-severe Atopic Dermatitis
Updated Oct 18, 2026. Something wrong or missing? Report it on the TRXB page.
See TRXB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
TRXB catalysts and pipeline →